Arkolith/Insider Trading/SUPN/Form 4

Gemayel Georges

DirectorSUPERNUS PHARMACEUTICALS, INC. (SUPN) · full profile →Form 4 · filed Feb 25, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 24, 2026Grant(A)4K—$038K
Feb 23, 2026Option exercise(M)15K$12.98$195K34K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 24, 2026Disposed to issuer(D)4K—$00
Feb 23, 2026Option exercise(M)15K—$00

Transaction Codes

A
Grant / award
M
Option exercise / conversion
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001256088-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML